CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today the appointments of Peter H. Reinhart, Ph.D., as Chief Scientific Officer and Gregory P. Licholai as Chief Operating Officer. Dr. Reinhart replaces interim CSO, Walter Newman, Ph.D., of Healthcare Ventures, who will remain with the company as a consultant.
